Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. National Cancer Institute, Bethesda, MD, United States

Survival: 7.6 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Bethesda, MD
Hospital: National Cancer Institute
Journal: Link
Date: 12/2012

Patients in this phase 2 study were divided into 2 groups based on their particular form of brain cancer. Group A consisted of 32 glioblastoma multiforme patients with a median age of 48 years and 63% male. Group B had 32 anaplastic glioma patients with a median age of 41 years and 75% male.

Patients in both groups were treated with the biologic therapy agent vandetanib, which is a VEGF inhibitor that interferes with tumor blood supply.

This study reported toxicities observed in both patient groups combined. There was one treatment-related death due to brain hemorrhage. Grade 4 lymphopenia, fatigue, and skin reactions were also reported.

The median overall survival rates for group A and B were 6.3 and 7.6 months, respectively.

Study drug was supplied by AstraZeneca.

Correspondence: Dr. Teri N. Kreisl; email:

E-mail to a Friend Email Physician More Information